Advance candidates with high-confidence proteomic insight
High-throughput protein measurements across every experiment. Absolute quantification. Faster, more confident iteration from hit to lead.
The Nomic Platform powers high-throughput proteomics for faster, more confident R&D decisions
Information Dense
Accelerate development decisions with actionable proteomic data.
Fast Iteration
Reduce turnaround times with high-throughput experimental feedback loops.
Interoperable Data
Unify candidate profiling with harmonized output across experiments and workflows.
Proteomics driving
drug R&D
Predicting clinical toxicity earlier with high-throughput proteomics
Late-stage toxicity failures remain one of the most costly and preventable problems in drug development. Nomic Omni 1000 accurately captures proteomic profiles that align with known clinical outcomes and detects liabilities missed by conventional assays, including compounds that later failed due to toxicity. By revealing toxicity signals at lower doses, researchers can identify risk earlier and more confidently select candidates.
Capture emergent biology from complex in vitro models
3D models, such as organoids, spheroids, tissue slices, microphysiological systems, can yield unique insights that emerge in disease-relevant settings, but capturing the complex inter-cellular interactions at play requires broad readouts. Omni 1000 profiling in patient-derived organoids simultaneously captures compound effects on ECM remodelling, angiogenesis, stress responses, immune interactions and cytotoxicity. Thus, protein profiling is uniquely suited to scale analyses of complex in vitro systems.
Data generated in collaboration with the Soragni Lab at UCLA
Characterize candidates early for improved prioritization
Advancing assets through drug discovery pipelines requires rapid, data-driven prioritization, yet simple phenotypic readouts readouts lack the ability to resolve distinct MOAs or capture off-target effects. Omni 1000 profiling in diverse model systems captures key readouts, while providing mechanistic resolution and toxicity insights.
In an anti-inflammatory screen in iPSC-derived microglia, LPS-induced TNFα suppression was shared across many compounds — making it insufficient alone to discriminate between candidates. Broader secretome profiling revealed the full picture: JAK and RIPK inhibitors produced clean, selective anti-inflammatory signatures, while others drove paradoxical pro-inflammatory signals or clear cytotoxicity markers. That resolution — distinguishing true immunomodulation from off-target liability across a wide compound set — enables confident prioritization before costly downstream failures.
Proteomics that supports you all the way
From discovery screening to drug R&D and clinical studies, Nomic provides a service that scales with your projects. Whether using Omni 1000, context-specific Core options, or even a tailored Flex panel designed to your objectives, you can adapt your approach without compromising data quality or cross study compatibility.
Discovery
- Target ID
- Therapeutic Biomarker Discovery
- Indication Selection
- Target Validation
- Perturbation Biology
- MoA Studies
- Early Tox Profiles
Drug R&D
- Target Engagement
- Hit-to-Lead
- Hit Optimization
- ADME/Tox
- Pre-clinical/IND Enabling
Translational
- Biomarker Validation
- Patient Stratification
- PK/PD
- Safety
- Disease Prognosis
Stop inferring biology. Start measuring it.
See how quantitative protein data drives decisions from target selection to patient stratification.
Resources for discovery teams
Your research project deserves a protein answer
Our scientists have designed proteomics studies across target ID, perturbationbiology, MoA, and early toxicity. Share the specifics of your program, and we will tell you what is possible.
